and 36% had benign diseases, the pleural fluid cytologic study was the best for establishing a diagnosis. The pleural fluid carcinoembryonic antigen (CEA) levels above 10 had a high specificity (90%) for malignancy but Most patients who are admitted to a hospital with a pleural effusion undergo extensive diagnostic procedures in an attempt to identify the cause of the effusion.'2 These procedures include chest radiograph, CT study of the thorax, thoracentesis with multiple chemical determinations, microbiologic studies on the pleural fluid, pleural fluid cytologic study, needle biopsy of the pleura, pleuroscopy, bronchoscopy, and open pleural biopsy.
This present study was undertaken with the following three goals: (1) to identify the relative frequency for which different diseases are responsible for pleural effusion in a large pulmonary referral hospital in Prague, Czech Republic; (2) to identify which procedures were useful in separating malignant from nonmalignant pleural effusions; and (3) to identify which procedures most commonly led to a The patients were asked a series of questions regarding their clinical history that included the duration of their illness and whether they had weight loss, dull chest pain, pleuritic chest pain, temperature elevation, etc. The breathlessness of the patient was semiquantitated by the scheme of the World Health Organization; grade 3 is breathlessness with minimal effort while grade 4 is breathlessness at rest. Patients were said to have an occupational asbestos exposure if they worked for more than 5 years at factories producing asbestos products. Patients were said to have work exposure to carcinogens if they worked for more than 2 years with uranium, chromium, or ammonia. Patients were divided by their smoking histories into nonsmokers, light smokers (up to 200,000 cigarettes lifetime), and heavy smokers (more than 200,000 cigarettes lifetime).
C1inical Investigations
The pleural fluid from all patients was examined macroscopically, ie, the color and the odor. The pleural fluid was also evaluated microscopically after it was stained with Wright's stain for the differential cell count. A pleural effusion was considered eosinophilic if it contained more than 5% eosinophils. A Gram's stain and an acid-fast stain of the pleural fluid were also examined.
The following laboratory examinations were made on the pleural fluid 4 and class 5 considered diagnostic of cancer. All patients in the study also underwent bronchoscopy, biopsy of the parietal pleura (unless gross pus was present in the pleural space), and perfusion lung scan. Thoracoscopy with direct visualization was performed in seven patients in whom malignancy was suspected but not proved after the other diagnostic procedures.
Pleural Effusion Criteria
The criteria we used for the more common causes of pleural effusion were the following.
Malignant Effusion: An effusion associated with malignancy in the pleural space as demonstrated by cytologic study, pleural biopsy specimen, or autopsy.
Paramalignant Effusion: A pleural effusion occurring in a patient with known malignancy but in whom the pleural fluid cytologic study and pleural biopsy specimen did not demonstrate malignancy and for whom there was no obvious alternative diagnosis. At autopsy, there could not be any direct involvement of the pleural space by malignancy.
Parapneumonic Effusion: An effusion associated with pneumonia, pulmonary abscess, or bronchiectasis. The pleural fluid was an exudate with a predominance of polymorphonuclear leukocytes.
Empyema: The accumulation of pus in the pleural space on which the Gram's stain was positive or the bacterial cultures were positive. With cytologic study, the polymorphonuclear leukocytes were partially or completely disintegrated.
Tuberculous Effusion: An effusion that met at least one of the following four criteria: (1) positive culture for Mycobacterium tuberculosis from pleural fluid or pleural biopsy specimen; (2) positive smear for acid-fast bacilli from pleural fluid; (3) caseating granuloma on pleural biopsy specimen; or (4) positive sputum culture for M tuberculois with either an exudative pleural effusion or noncaseating granuloma in pleural biopsy specimen.
Heart Failure Effusion: A pleural effusion in the setting of clinical congestive heart failure with an enlarged heart, distended neck veins, and cardiac gallop that improved with therapy for the congestive heart failure.
Hemothorax: The hematocrit in the pleural fluid was required trauma, a history of trauma was required. For the nontraumatic hemothorax, other reasons for bleeding, eg, hemophilia or thoracic endometriosis, were required. Pancreatic Pleural Effusion: A pleural effusion with a high amylase level in a patient with acute or chronic disease of the pancreas in whom rupture of the esophagus and bronchogenic carcinoma had been excluded.
Effusion due to pulmonary embolism: A pleural effusion in a patient with a lung scan showing a high probability of a pulmonary embolus or a pulmonary arteriogram demonstrating pulmonary emboli.
Asbestos Pleural Effusion: A pleural effusion in a patient with a history of asbestos exposure in whom there was no other obvious cause of pleural effusion. In addition, these patients were required to have no other disease process with a follow-up of at least 2 years.
Rheumatoid Effusion: An effusion that occurred in a patient with rheumatoid arthritis and that was characterized by a low glucose level, low pH, a high LDH level, and negative bacterial cultures.
Uremic Pleural Effusion: An exudative effusion that occurred in a patient with uremia for which there was no other explanation.
Intra-abdominal Process: An effusion that accompanied an intra-abdominal inflammatory process such as pericholecystitis or hepatic abscess.
Myxedematous Effusion: An effusion that occurred in conjunction with myxedema and pericardial effusion.
At the end of the study, we reviewed each patient's chart to see what procedures were most valuable in establishing the cause of the effusion.
Statistical Methods
The data were entered into a computer (Hewlett-Packard 2100 S). For data analysis, the patients were divided into those with malignancy (malignant group) and those with benign disease (benign group). The (Table 2 ). The patients with malignancy were more likely to have a history of working with carcinogens or to have a personal history of malignancy. The incidence of dull chest pain was higher in the group with malignancy while the incidence of pleuritic chest pain was higher in the group with benign disease. The patients with malignancy tended to have more shortness of breath. There was no significant differences in the two groups with respect to their smoking history, the prevalence of chronic bronchitis, cough, or hemotypsis.
There were also statistically significant differences when we looked at the results of the laboratory tests in the two different groups ( Table 3 ). The patients with malignancy had a significantly higher serum LDH, CEA and tissue polypeptide level than did those with benign disease, while those with benign disease had a significantly higher serum protein level. The patients with malignancy had a significantly higher pleural fluid level of alkaline phosphatase and CEA than did those with benign disease. The IgM levels in the serum and pleural fluid were signifi- cantly lower in the malignant group. There were no significant differences in the serum or pleural fluid glucose level, IgG level, IgA level, amylase level, cholesterol, C3 fraction of complement, or C4 fraction of complement. The frequency of pleural fluid eosinophilia was significantly higher in those with benign disease (11.2%) than in those with malignant disease (0.9%). The pleural fluid pH did not differ significantly between those with malignant and those with benign disease. Even though there were significant differences in the mean levels of some of the biochemical measurements in the two groups, such measurements were of limited value in definitively separating the two groups ( Table 4 ). The three measures involving the CEA (serum CEA, pleural fluid CEA, and ratio of pleural fluid/serum CEA) all had specificities that were close to 90%, but the sensitivities of none exceeded 40%.
When the biochemical parameters were compared in the patients with malignant pleural effusion and paramalignant pleural effusion, the only measure that differed significantly (p<0.05) was the CEA level. For the patients with malignant pleural effusions, the CEA level exceeded 10 ng/mL in 35 of 70 (50%) and exceeded 20 ng/mL in 26 of 70 (37%), while in the paramalignant effusions, the CEA level exceeded 10 ng/mL in only 5 of 26 (19%) and exceeded 20 ng/mL in only 2 of 26 (12%).
After the diagnostic process was completed, we evaluated which procedure was most important in delineating the causes of the effusion (Table 5 ). Cytologic study, which included the Wright's stain (for polymorphonuclear leukocytes, lymphocytes, mesothelial cells, and eosinophils) and the Papanicolaou stain for malignant cells, was the most definitive procedure in 60.8% of the patients, including 60 with malignancy and 18 with inflammatory-type effusions. Needle biopsy specimen of the pleura was diagnostic by itself in four patients. The combination of cytologic and histologic study was most helpful in 26 cases, including 10 malignant and 16 inflammatory effusions. Bronchoscopy was the definitive study in 12 cases, while radiographs, biochemistry, and bacteriologic cultures were the definitive study in 7, 6, and 5 patients, respectively.
Based on the above analysis we could break down the diagnostic workup of patients with pleural effusions into four steps. The diagnostic yields with each of the steps are shown in Table 6 . Note that the first step involves only the clinical evaluation plus the cytologic study of the pleural effusion and this gives a diagnosis in more than one third of the patients. By the time the first two steps are completed, more than 60% of the patients have a diagnosis and no invasive procedure has been necessary. With this four-step workup, thoracoscopy or an open pleural biopsy was needed in less than 5% of patients.
DISCUSSION
During the 4-year study period, we evaluated 171 patients with pleural effusions who were seen at the Pneumological Clinic. The most common underlying disease in this series was malignancy (63%). The other leading underlying diseases were pneumonia (13.4%) and tuberculosis (6.4%). The high incidence of malignant effusion in the present series is influenced by the character of our clinic, which acts as a differential diagnostic center for pulmonary tumors in the Central Bohemia Region. Indeed in an epidemiologic study performed in parallel with the present study, only 22% of the newly discovered pleural effusions were due to malignancy while 46% were due to congestive heart failure.3
The results of the present study are markedly different than those reported in a similar study carried out by Tousek, 4 in the 1955 to 1960 period, in a district hospital in eastern Bohemia. He reported that the most common cause for the effusion was tuberculosis (36.5%), followed by malignancy (17%) and congestive heart failure (15%). The Strapko and Olosova5 demonstrated that the percentage of effusions that were due to malignancy was increasing.
It should be emphasized that the distribution of diagnoses responsible for pleural effusions is heavily dependent on the locality and the type of hospital (referral vs primary care). For example, in Rwanda6 more than 80% of pleural effusions at a referral hospital are due to tuberculosis and most of the patients with tuberculous pleuritis are HIV positive. In a recent study from a referral hospital in northern Spain,7 nonmalignant disease was responsible for slightly more than 50% of pleural effusions, and tuberculosis was responsible for 50% of the benign effusions. One of the primary reasons for the higher percentage of malignancy in the present series is the small number of patients with tuberculosis. The explanation for the low incidence of congestive heart failure in this series is due to the fact that the Pneumological Clinic is a referral center for patients with lung disease. Indeed, in an epidemiologic report from the Czech Republic, congestive heart failure was the most common cause of pleural effusion.3
In the present series, lung cancer accounted for approximately 60% of all malignant pleural effusions. Previous authors7-9 have reported that only 30 to 40% of patients with malignant pleural effusions have lung cancers. We believe that the true figure in the Czech Republic is probably closer to 40%. The present study is biased toward a higher percentage of lung cancer since the Pneumological Clinic at the Charles University serves as a diagnostic center for lung cancer in the area of Prague with a catchment area of approximately 1 million. The incidence of lung cancer in the Czech Republic is 99.7/100,000 in men and 15/100,000 in women, rates that are slightly Since most patients at the Pneumonological Clinic have lung cancer, it might seem surprising that bronchoscopy was not more useful in establishing the cause for the pleural effusion. In our clinic, the biopsy diagnosis of lung cancer is most commonly established by bronchoscopy, but bronchoscopy does not delineate the cause of a pleural effusion with the exception of some paramalignant effusions. The yield from needle biopsy in the present series (25% with pleural malignancy and 36% with pleural tuberculosis) is lower than that reported in most series.1 We attribute this low diagnostic yield to the fact that these were the first patients subjected to needle biopsy in our institution. Our diagnostic yields with this procedure have tended to improve with time. Based on our experience in the present study, we recommend that clinicians give consideration to the four-step workup outlined in Table 6 in the evaluation of a patient in a referral center where the incidence of malignancy is high. We hasten to add that the workup of a patient should be individualized.
In step 1, when the patient is first evaluated, a careful history and physical examination should be obtained and a diagnostic thoracentesis should be performed. We would recommend measurement of the levels of protein and LDH to ascertain if the fluid is a transudate or an exudatell and pleural fluid cytologic study. If the patient has an acute febrile illness or if the pleural fluid smells putrid or is turbid, the fluid should be analyzed with Gram's stain and aerobic and anaerobic cultures should be obtained.
In step 2, a second cytologic study is obtained and the pleural fluid and serum are sent for tumor markers (CEA and tissue polypeptide antigen) and the pleural fluid is sent for glucose, amylase levels, differential cell count, and bacteriologic studies if they had not been obtained previously.
In step 3, the patient is subjected to one or more invasive procedures. The initial procedure will depend on the clinical situation. If pleural tuberculosis Clinical Investigations or malignancy is strongly suspected, the procedure should probably be needle biopsy of the parietal pleura, while if pulmonary embolism is thought to be most likely, a lung scan should be obtained. Bronchoscopy is recommended at this point, although it is frequently not diagnostic if the patient does not have a parenchymal infiltrate or hemoptysis.12
In step 4, the patient is subjected to thoracoscopy or open pleural biopsy. Thoracoscopy can establish the diagnosis of pleural malignancy, including mesothelioma in approximately 90% of patients,'3"14 but is rarely diagnostic of benign disease. Since in most series, a sizable percentage of patients recover from an episode of a pleural effusion without any cause ever being obtained and we think that these patients have viral pleuritis, we recommend proceeding to step 5 only if the patient's condition is not improving or if the patient demands assurance that he does not have a cancer.
